7498 Results (Page 231 of 300)
Pharmaceuticals Markets Research Reports
Thailand Cardiovascular Diseases Therapeutics Market Analysis
The Thailand cardiovascular disease therapeutics market is projected to grow from $195 Mn in 2022 to $350 Mn in 2030 with a CAGR of 7.56% for the year 2022-2030. The increasing elderly population and the rising demand for novel therapeutic options for cardiovascular diseases are the major market drivers for the growth of the market. The Thailand cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Silom Medical, Onimax, and Sun Pharmaceutical are the major players in the Thailand cardiovascular disease therapeutics market.
South Korea Cardiovascular Diseases Therapeutics Market Analysis
The South Korean cardiovascular disease therapeutics market is projected to grow from $2.37 Bn in 2022 to $4.47 Bn in 2030 with a CAGR of 8.22% for the year 2022-2030. The increasing awareness of cardiovascular diseases and the rising ageing population are responsible for the growth of the market. The South Korean cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Kolmar, Kwang Dong Pharmaceutical, and AstraZeneca are the major players in the South Korean cardiovascular disease therapeutics market.
South Africa Cardiovascular Diseases Therapeutics Market Analysis
The South African cardiovascular disease therapeutics market is projected to grow from $1.05 Bn in 2022 to $2.02 Bn in 2030 with a CAGR of 8.45% for the year 2022-2030. The rising elderly population leading to the increasing incidence of cardiovascular diseases in South Africa is responsible for the growth of the market. The South African cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Wraps, Afriplex, and Daiichi Sankyo are the major players in the South African cardiovascular disease therapeutics market.
Saudi Arabia Cardiovascular Diseases Therapeutics Market Analysis
The Saudi Arabia cardiovascular disease therapeutics market is projected to grow from $2.76 Bn in 2022 to $5.39 Bn in 2030 with a CAGR of 8.72% for the year 2022-2030. Increased healthcare spending and government initiatives like Vision 2030 in Saudi Arabia are the major market drivers for the growth of the market. The Saudi Arabia cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Saudi Centre Group, Riyadh Pharma, and Gilead Sciences are the major players in the Saudi Arabia cardiovascular disease therapeutics market.
Philippines Cardiovascular Diseases Therapeutics Market Analysis
The Philippines cardiovascular disease therapeutics market is expected to witness growth from $358 Mn in 2022 to $649 Mn in 2030 with a CAGR of 7.72% for the forecasted year 2022-2030. due to the rising prevalence of cardiovascular diseases in the Philippines. Furthermore, the increase in healthcare spending in the Philippines has resulted in the expansion of the market. The Philippines cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Prosel Pharmaceuticals, Morishita-Segg'S Pharmaceuticals, and Fresenius Kabi are the major players in the Philippines cardiovascular disease therapeutics market.
Netherlands Cardiovascular Diseases Therapeutics Market Analysis
The Netherlands cardiovascular disease therapeutics market is expected to witness growth from $423 Mn in 2022 to $767 Mn in 2030 with a CAGR of 7.72% for the year 2022-2030. The Netherlands being the hub for rising trends in biochemistry, genetics, and molecular biology and the increase in demand for advanced therapeutics for the treatment of cardiovascular diseases in the Netherlands are the major factors responsible for the expansion of the market. The Netherlands cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Northsea Therapeutics, Dannalab, and AstraZeneca are the major players in the Netherlands cardiovascular disease therapeutics market.
Malaysia Cardiovascular Diseases Therapeutics Market Analysis
The Malaysia cardiovascular disease therapeutics market is projected to grow from $261 Mn in 2022 to $464 Mn in 2030 with a CAGR of 7.42% for the year 2022-2030. The rising elderly population and increased prevalence of cardiovascular diseases in Malaysia are the major factors responsible for the growth of the market. The Malaysia cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Xepa-Soul Pattinson, Hyphens Pharma, and Novartis are the major players in the Malaysia cardiovascular disease therapeutics market.
Egypt Cardiovascular Diseases Therapeutics Market Analysis
The Egypt cardiovascular disease therapeutics market is expected to witness growth from $455 Mn in 2022 to $889 Mn in 2030 with a CAGR of 8.72% for the year 2022-2030. The increasing elderly population in Egypt and the government initiatives like Back to Rhyth and the Nile Heart Challenge to increase awareness about cardiovascular disease in Egypt are the major growth drivers of the market. The Egypt cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Copad Pharma, Menarini Pharmaceutical, and Novartis are the major players in the Egypt cardiovascular disease therapeutics market.
UK Depression Therapeutics Market Analysis
The UK depression therapeutics market is expected to witness growth from $263 Mn in 2022 to $338 Mn in 2030 with a CAGR of 3.2% for the forecast year 2022-2030. The rising cases of depression in the UK particularly in the younger generation and their subsequent demand for novel therapeutic options are responsible for the growth of the market. The UK depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Curium Pharma, Chatfield Pharmaceuticals, and Abbott Laboratories are the major players in the UK depression therapeutics market.
Spain Depression Therapeutics Market Analysis
The Spain depression therapeutics market is expected to witness growth from $195 Mn in 2022 to $271 Mn in 2030 with a CAGR of 4.2% for the forecasted year 2022-2030. The increasing incidence of depression in Spain and rising healthcare expenditure are the major growth drivers of the market. The Spain depression therapeutics market is segmented by drug type, therapies, indication, and by end users. TecnyFarma, Pharmaloop, and Pfizer are the major players in the Spain depression therapeutics market.
Philippines Depression Therapeutics Market Analysis
The Philippines' depression therapeutics market is expected to witness growth from $22 Mn in 2022 to $35 Mn in 2030 with a CAGR of 5.7% for the forecasted year 2022-2030. The rising investments in developing depression medications in the Philippines and the growing economy of the Philippines are responsible for the expansion of the market. The Philippines depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Maridan, MedChoice Pharma, and AstraZeneca are the major players in the Philippines' depression therapeutics market.
Japan Depression Therapeutics Market Analysis
The Japan depression therapeutics market is expected to witness growth from $628 Mn in 2022 to $978 Mn in 2030 with a CAGR of 5.7% for the forecasted year 2022-2030. The growth in research and development initiatives in Japan and the increasing prevalence of depression among the Japanese population are driving the growth of the market. The Japan depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, and AstraZeneca are the major players in the Japan depression therapeutics market.
Italy Depression Therapeutics Market Analysis
The Italy depression therapeutics market is expected to witness growth from $242 Mn in 2022 to $350 Mn in 2030 with a CAGR of 4.7% for the forecasted year 2022-2030. The rising incidence of depression in Italy and the growing demand for novel therapeutics are responsible for the growth of the market. The Italy depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Procos, Indena, and Cipla are the major players in the Italy depression therapeutics market.
India Depression Therapeutics Market Analysis
The India depression therapeutics market is expected to witness growth from $184 Mn in 2022 to $345 Mn in 2030 with a CAGR of 8.2% for the forecasted year 2022-2030. The increasing investments in research and development projects for depression in India along with supportive government policies are responsible for the growth of the market. The Indian depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Mediwin Pharmaceuticals, Zydus Cadila, and GlaxoSmithKline are the major players in the Indian depression therapeutics market.
Germany Depression Therapeutics Market Analysis
The German depression therapeutics market is expected to witness growth from $370 Mn in 2022 to $483 Mn in 2030 with a CAGR of 3.4% for the forecasted year 2022-2030. The growing awareness of depression and the rising technological advancements like telemedicine and digital therapeutics are the major market drivers. The German depression therapeutics market is segmented by drug type, therapies, indication, and by end users. ix Therapeutics, Denk Pharma, and AstraZeneca are the major players in the German depression therapeutics market.
France Depression Therapeutics Market Analysis
The France depression therapeutics market is expected to witness growth from $278 Mn in 2022 to $386 Mn in 2030 with a CAGR of 4.2% for the forecasted year 2022-2030. The rising incidence of depression and the development of several innovative treatments for depression in France are the major market drivers. The France depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Pharmaleads, Elaiapharm, and AbbVie are the major players in the France depression therapeutics market.
Egypt Depression Therapeutics Market Analysis
The Egypt depression therapeutics market is expected to witness growth from $28 Mn in 2022 to $48 Mn in 2030 with a CAGR of 6.7% for the forecasted year 2022-2030. The growing incidence of depression in Egypt and its improving health infrastructure has resulted in the growth of the market. The Egypt depression therapeutics market is segmented by drug type, therapies, indication, and by end users. FPi Future Pharmaceutical, Quadri Pharma, and GlaxoSmithKline are the major players in the Egypt depression therapeutics market.
Brazil Depression Therapeutics Market Analysis
The Brazil depression therapeutics market is expected to witness growth from $253 Mn in 2022 to $409 Mn in 2030 with a CAGR of 6.2% for the forecasted year 2022-2030. The rise in healthcare spending and new research and development projects for depression treatment by various pharmaceutical firms in Brazil are responsible for the expansion of the market. The Brazil depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Neo Química, Mantecorp Farmasa, and Elly Lilly are the major players in the Brazil depression therapeutics market.
Australia Depression Therapeutics Market Analysis
The Australian depression therapeutics market is expected to witness growth from $121 Mn in 2022 to $204 Mn in 2030 with a CAGR of 6.7% for the forecasted year 2022-2030. The development of newer and innovative therapeutics by Australian pharmaceutical companies and the increased demand for personalized depression treatment in Australia are driving the growth of the market. The Australian depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Kira Biotech, Zucero Therapeutics, and Pfizer are the major players in the Australian depression therapeutics market.
UAE Liver Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the UAE liver cancer therapeutics market will reach a value of $57.3 Mn from $14.7 Mn in 2022, growing at a CAGR of 18.6% during 2022-30. The liver cancer therapeutics in UAE is dominated by a few domestic pharmaceutical companies such as Neopharma, Julphar, and Medpharma. The liver cancer therapeutics market in UAE is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
Philippines Liver Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the Philippines liver cancer therapeutics market will reach a value of $24.4 Mn from $6.45 Mn in 2022, growing at a CAGR of 18.1% during 2022-30. The liver cancer therapeutics market in the Philippines is dominated by a few domestic pharmaceutical companies such as United Laboratories, Pascual Laboratories, and Philippine Pharma Resources. The liver cancer therapeutics market in the Philippines is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
Japan Liver Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the Japan liver cancer therapeutics market will reach a value of $689.2 Mn from $182.12 Mn in 2022, growing at a CAGR of 18.1% during 2022-30. The liver cancer therapeutics market in Japan is dominated by a few domestic pharmaceutical companies such as Chugai Pharmaceutical, Taiho Pharmaceutical, and Eisai. The liver cancer therapeutics market in Japan is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
Indonesia Liver Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the Indonesia liver cancer therapeutics market will reach a value of $64.3 Mn from $17.58 Mn in 2022, growing at a CAGR of 17.6% during 2022-30. The liver cancer therapeutics market in Indonesia is dominated by a few domestic pharmaceutical companies such as Chugai Pharmaceutical, Taiho Pharmaceutical, and Eisai. The liver cancer therapeutics market in Indonesia is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
India Liver Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the India liver cancer therapeutics market will reach a value of $238.4 Mn from $53.3 Mn in 2022, growing at a CAGR of 20.6% during 2022-30. The liver cancer therapeutics in India is dominated by a few domestic pharmaceutical companies such as Dr. Reddy's Laboratories, HCG Hospitals, and Natco Pharma. The liver cancer therapeutics market in India is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
Egypt Liver Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the Egypt liver cancer therapeutics market will reach a value of $33.2 Mn from $8.2 Mn in 2022, growing at a CAGR of 19.1% during 2022-30. The liver cancer therapeutics market in Egypt is dominated by a few domestic pharmaceutical companies such as Pharco Pharmaceuticals, EIPICO, and Memac Pharma. The liver cancer therapeutics market in Egypt is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
